Ackman Uses Interesting Strategy, Including 'Superman' In Zoetis BidMark Melin
In setting up his next target, Zoetis Inc (NYSE:ZTS), activist hedge fund manager Bill Ackman has utilized an interesting combination of derivatives and may be employing a new tactic with a potential partner in a takeover bid, namely with the rumored involvement of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX).
Several weeks ago, as Pershing Square Capital was in court with Allergan, Inc. (NYSE:AGN), Ackman’s hedge fund acquired roughly 41.8 million . . .
This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here
If you are subscribed and having an account error please clear cache and then cookies if that does not work email firstname.lastname@example.org and we will get back to you as quick as humanly possible